Entries by Sarah Russo

Safety and Efficacy of Medical Cannabis Oil for Behavioral and Psychological Symptoms of Dementia: An-Open Label, Add-On, Pilot Study

Authors: Assaf Shelef, Yoram Barak, Uri Berger, Diana Paleacu, Shelly Tadger, Igor Plopsky, Yehuda Baruch
Journal of Alzheimer’s Disease, 27 February 2016

BACKGROUND: Tetrahydrocannabinol (THC) is a potential treatment for Alzheimer’s disease (AD). OBJECTIVE: To measure efficacy and safety of medical cannabis oil (MCO) containing THC as an add-on to pharmacotherapy, in relieving behavioral and psychological symptoms of dementia…

,

Cannabinoids to treat spinal cord injury.

Authors: Angel Arevalo-Martin, Eduardo Molina-Holgado, Daniel Garcia-Ovejero
Progress in Neuro-Psychopharmacology and Biological Psychiatry, 4 January 2016

Spinal cord injury (SCI) is a devastating condition for which there is no standard treatment beyond rehabilitation strategies. In this review, we discuss the current knowledge on the use of cannabinoids to treat this condition. The endocannabinoid system is expressed in the in…

Preferential epithelial expression of type-1 cannabinoid receptor (CB1R) in the developing canine embryo.

Authors: Andrea Pirone, Carla Lenzi, Alessandra Coli, Elisabetta Giannessi, Maria Rita Stornelli, Vincenzo Miragliotta
SpringerPlus, 22 December 2015

The use of cannabinoid receptor agonists is gaining a strong interest both in human and veterinary medicine. The potential use of cannabimimetic compounds in companion animals was reviewed in 2007 for their role in tissue inflammation and pain. A better knowledge of type-1 can…

Molecular Targets of Cannabidiol in Neurological Disorders.

Authors: Clementino Ibeas Bih, Tong Chen, Alistair V. W. Nunn, Michaël Bazelot, et al
Neurotherapeutics, October 2015

Cannabis has a long history of anecdotal medicinal use and limited licensed medicinal use. Until recently, alleged clinical effects from anecdotal reports and the use of licensed cannabinoid medicines are most likely mediated by tetrahydrocannabinol by virtue of: 1) this canna…

,

Cannabidiol for the Prevention of Graft-versus-Host-Disease after Allogeneic Hematopoietic Cell Transplantation: Results of a Phase II Study.

Authors: Moshe Yeshurun, Ofer Shpilberg, Corina Herscovici, Liat Shargian, Juliet Dreyer, et al
Biology of Blood and Marrow Transplantation, October 2015

Graft-versus-host-disease (GVHD) is a major obstacle to successful allogeneic hematopoietic cell transplantation (alloHCT). Cannabidiol (CBD), a nonpsychotropic ingredient of Cannabis sativa, possesses potent anti-inflammatory and immunosuppressive properties. We hypothesized…

Δ⁹-Tetrahydrocannabinol attenuates allogeneic host-versus-graft response and delays skin graft rejection through activation of cannabinoid receptor 1 and induction of myeloid-derived suppressor cells.

Authors: Jessica M. Sido, Prakash S. Nagarkatti, Mitzi Nagarkatti
Journal of Leukocyte Biology, September 2015

Immune cells have been shown to express cannabinoid receptors and to produce endogenous ligands. Moreover, activation of cannabinoid receptors on immune cells has been shown to trigger potent immunosuppression. Despite such studies, the role of cannabinoids in transplantation…

Cannabinoids for the Treatment of Movement Disorders.

Authors: Briony Catlow, Juan Sanchez-Ramos
Current Treatment Options in Neurology, September 2015

Use of cannabinoids as medications has a long history. Unfortunately, the prohibition of cannabis and its classification in 1970 as a schedule 1 drug has been a major obstacle in studying these agents in a systematic, controlled manner. The number of class 1 studies (randomize…

The psychoactive compound of Cannabis sativa, Δ(9)-tetrahydrocannabinol (THC) inhibits the human trophoblast cell turnover.

Authors: M.A. Costa, B.M. Fonseca, F. Marques, N.A. Teixeira, G. Correia-da-Silva
Toxicology, 6 August 2015

The noxious effects of cannabis consumption for fertility and pregnancy outcome are recognized for years. Its consumption during gestation is associated with alterations in foetal growth, low birth weight and preterm labor. The main psychoactive molecule of cannabis, Δ(9)-tetr…

Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy.

Authors: Alexandra L. Geffrey, Sarah F. Pollack, Patricia L. Bruno, Elizabeth A. Thiele
Epilepsia, August 2015

OBJECTIVE: Under an expanded access investigational new drug (IND) trial, cannabidiol (CBD) is being studied as a possible adjuvant treatment of refractory epilepsy in children. Of the 25 subjects in the trial, 13 were being treated with clobazam (CLB). Because CLB and CBD are…

Turning Over a New Leaf: Cannabinoid and Endocannabinoid Modulation of Immune Function.

Authors: Guy A. Cabral, Thomas J. Rogers, Aron H. Lichtman
Journal of Neuroimmune Pharmacology, June 2015

Cannabis is a complex substance that harbors terpenoid-like compounds referred to as phytocannabinoids. The major psychoactive phytocannabinoid found in cannabis ∆(9)-tetrahydrocannabinol (THC) produces the majority of its pharmacological effects through two cannabinoid recep…